Harvard Bioscience
HBIO
80 hedge funds and large institutions have $143M invested in Harvard Bioscience in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
23% more capital invested
Capital invested by funds: $116M → $143M (+$26.6M)
13% more funds holding
Funds holding: 71 → 80 (+9)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.89% more ownership
Funds ownership: 6.54% → 7.43% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.71M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$2.61M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.31M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.55M |
| 5 |
RA
Royce & Associates
New York
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$1.22M |
| 2 |
Millennium Management
New York
|
-$847K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$812K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$552K |
| 5 |
Axa
Paris,
France
|
-$491K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | -$5.48K | -107 | -51% |
|
|
SWM
77
SeaCrest Wealth Management
Purchase,
New York
| $4K | – | – | – |
|
|
PIA
78
Piedmont Investment Advisors
Durham,
North Carolina
| $3K | +$3.13K | +61 | New |
|
79
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1K | -$17.4K | -339 | -96% |
|
80
SEI Investments
Oaks,
Pennsylvania
| $1K | -$6.45K | -126 | -91% |
|
|
81
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$552K | -11,041 | Closed |
|
|
82
Axa
Paris,
France
| – | -$491K | -9,815 | Closed |
|
83
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$383K | -7,661 | Closed |
|
|
BCM
84
BlueCrest Capital Management
St Helier,
Jersey
| – | -$200K | -3,997 | Closed |
|
|
ECM
85
Element Capital Management
New York
| – | -$130K | -2,606 | Closed |
|
86
Citadel Advisors
Miami,
Florida
| – | -$64K | -1,281 | Closed |
|
|
AIM
87
Alambic Investment Management
Belvedere,
California
| – | -$54K | -1,080 | Closed |
|
|
TRCT
88
Tower Research Capital (TRC)
New York
| – | -$26K | -513 | Closed |
|
HBIO Hedge Fund Activity: Q2 2018 in Review
80 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2018, worth a combined $143M — up 23% from $116M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new HBIO positions and 8 closed out — a net gain of 9 holders — while 28 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $7.71M. The largest seller was Foundry Partners, cutting an estimated $1.22M.
- 80 institutional investors held Harvard Bioscience (HBIO) as of Q2 2018, up from 71 in Q1 2018.
- Funds reported $143M of Harvard Bioscience stock for Q2 2018, up 23% quarter-over-quarter.
- 17 funds opened new Harvard Bioscience positions in Q2 2018 and 8 closed out, a net change of +9 holders.
- The largest Harvard Bioscience buyer in Q2 2018 was BlackRock, an estimated $7.71M added.
- The largest Harvard Bioscience seller in Q2 2018 was Foundry Partners, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2018.